AstraZeneca sells Crohn's drug US rights for $380M

Pharmaceuticals manufacturer Perrigo Company, based in Dublin, Ireland, acquired the U.S. rights to a Crohn's disease drug from AstraZeneca, a London-based biopharmaceutical company.

Perrigo bought the rights to Entocort, a drug for mild to moderate Crohn's disease, for $380 million. Additionally, Perrigo plans to acquire generic Entocort capsules marketed by Par Pharmaceuticals.  

"Our agreement with Perrigo completes the global divestment of Entocort, emphasizing our strategic focus on three main therapy areas and providing further simplification of our supply chain," Luke Miels, an AstraZeneca executive vice president.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast